People
McKenzie Cato's expertise is assisting medical device, pharmaceutical, and other life science industry companies with pre- and post-market FDA regulatory topics. McKenzie helps companies in developing their regulatory strategy, preparing regulatory submissions, responding to FDA requests for information and data, drafting regulatory policies and procedures, and reviewing advertising and promotional materials. McKenzie also assists companies with FDA, DOJ, and DEA enforcement matters, regulatory due diligence, and state regulatory and licensing issues.
Juris Doctor, George Washington University Law School, honors
B.S. Chemistry, Georgetown University
District of Columbia
April 30, 2024
LDT Final Rule: Shifting the LDT Battlefield
April 25, 2024
FDA Updates Draft Guidance on Promotional Labeling and Advertising Considerations for Biological Reference Products and Biosimilars
March 25, 2024
FDA Publishes White Paper on Artificial Intelligence & Medical Products
April 30, 2024
LDT Final Rule: Shifting the LDT Battlefield
April 25, 2024
FDA Updates Draft Guidance on Promotional Labeling and Advertising Considerations for Biological Reference Products and Biosimilars
March 25, 2024
FDA Publishes White Paper on Artificial Intelligence & Medical Products
Juris Doctor, George Washington University Law School, honors
B.S. Chemistry, Georgetown University
District of Columbia